Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse long-term effects of reocclusion after coronary thrombolysis.
Brouwer MA, Böhncke JR, Veen G, Meijer A, van Eenige MJ, Verheugt FW. Brouwer MA, et al. Among authors: verheugt fw. J Am Coll Cardiol. 1995 Nov 15;26(6):1440-4. doi: 10.1016/0735-1097(95)00355-X. J Am Coll Cardiol. 1995. PMID: 7594068 Free article.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, et al. Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6. Lancet. 1999. PMID: 10475182 Clinical Trial.
Warfarin for ischemic heart disease.
Verheugt FW. Verheugt FW. Cardiol Rev. 2001 Nov-Dec;9(6):325-8. doi: 10.1097/00045415-200111000-00008. Cardiol Rev. 2001. PMID: 11696261 Review.
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, Pehrsson K, Verheugt FW, Meyer J, Betriu A, Califf RM, Li X, Fox NL; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Van de Werf F, et al. Among authors: verheugt fw. Eur Heart J. 2001 Dec;22(24):2253-61. doi: 10.1053/euhj.2001.2686. Eur Heart J. 2001. PMID: 11728145 Clinical Trial.
Oral anticoagulation for acute coronary syndromes.
Brouwer MA, Verheugt FW. Brouwer MA, et al. Among authors: verheugt fw. Circulation. 2002 Mar 19;105(11):1270-4. doi: 10.1161/hc1102.105594. Circulation. 2002. PMID: 11901033 No abstract available.
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, van Boven AJ, Vromans RP, Uijen GJ, Verheugt FW. Brouwer MA, et al. Among authors: verheugt fw. Circulation. 2002 Aug 6;106(6):659-65. doi: 10.1161/01.cir.0000024408.81821.32. Circulation. 2002. PMID: 12163424 Clinical Trial.
622 results